- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05787418
HH-120 Nasal Spray for Post-exposure Prevention of SARS-CoV-2
September 27, 2023 updated by: Huahui Health
A Phase III, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of HH-120 Nasal Spray for Post-exposure Prophylaxis of SARS-CoV-2
This study will assess the efficacy of HH-120 nasal spray in participants for the post-exposure prevention of SARS-CoV-2.
Study Overview
Status
Recruiting
Conditions
Intervention / Treatment
Detailed Description
During this study, participants will receive HH-120 nasal spray treatment for 7 consecutive days, the efficacy and safety of HH-120 nasal spray will be assessed throughout the study period mainly based on the incidence of symptomatic SARS-CoV-2 infection and adverse events, respectively.
Study Type
Interventional
Enrollment (Estimated)
1200
Phase
- Phase 3
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Mengwei Li
- Phone Number: +86 010-80766688
- Email: limengwei@hhhbio.com
Study Contact Backup
- Name: Ning Wu
- Phone Number: +86 010-80766688
- Email: wuning@hhhbio.com
Study Locations
-
-
-
Beijing, China, 100000
- Recruiting
- Beijing Ditan Hospital, Capital Medical University
-
Shanghai, China, 200000
- Recruiting
- Huashan Hospital of Fudan University
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
12 years to 85 years (Child, Adult, Older Adult)
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- 12 to 85 years old.
- Participants with potential exposure to index patients (with known positive result of qRT-PCR or rapid antigen test [RAT]).
- Participants will be randomized no longer than 48 hours from the onset of the COVID-19 related symptom of the index patients.
- Participants with a negative RAT result within 2 hours prior to randomization.
- Fertile participants must agree to use a highly effective method of contraception.
- Participants being able and willing to provide informed consent prior to any study-specific procedure.
Exclusion Criteria:
- Those with high risk of cardiac events, or severe abnormal functions of liver, kidney, lung, brain and other organs and are deemed as unsuitable to participate in the study (except for those subjects with kidney failure but received regular dialysis, or those with liver dysfunction but stabilized after treatment evaluated by the evaluation of the investigators).
- Those comorbid with asthma.
- Those with a history of SARS-CoV-2 infection within 3 months prior to randomization.
- Those who has received any nasal spray or aerosol inhalation COVID-19 vaccine within 3 months prior to randomization.
- Those who experienced symptom of upper respiratory tract infection within 2 weeks prior to randomization, such as nasal congestion, sore throat, shortness of breath (dyspnea), cough, fatigue, fever, headache, etc.
- Known history of allergy or reaction to any component of the study drug formulation.
- Those who has received other treatment with anti-COVID-19 indication (within 1 month or 5 half-life period prior to randomization, whichever occurs first).
- Participants with nasal disease that is inconvenient or intolerant of nasal spray administration.
- Other reasons considered by the investigator to be unsuitable for the study.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Placebo Comparator: Control group
Placebo
|
Placebo 8 times per day for 7 consecutive days
|
Experimental: HH-120 group
HH-120 Nasal Spray
|
HH-120 nasal spray 8 times per day for 7 consecutive days
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
The incidence of symptomatic SARS-CoV-2 infection
Time Frame: Up to 7 days
|
Incidence of participants with quantitative Real-Time polymerase chain reaction (qRT-PCR) confirmed SARS-CoV-2 infection and COVID-19 related symptom
|
Up to 7 days
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
The incidence of SARS-CoV-2 infection
Time Frame: Up to 7 days
|
Up to 7 days
|
The changes in SARS-CoV-2 viral nucleic acid load
Time Frame: Up to 7 days
|
Up to 7 days
|
The change of viral load by qRT-PCR
Time Frame: Up to 7 days
|
Up to 7 days
|
Incidence and severity of adverse events
Time Frame: Up to 21 days
|
Up to 21 days
|
The incidence of symptomatic SARS-CoV-2 infection
Time Frame: Up to 3 days
|
Up to 3 days
|
The incidence of symptomatic SARS-CoV-2 infection
Time Frame: Up to 5 days
|
Up to 5 days
|
Time to onset of first COVID-19 related symptom
Time Frame: Up to 7 days
|
Up to 7 days
|
Proportion of participants who progress to moderate/severe/critical type of COVID-19 or death
Time Frame: Up to 21 days
|
Up to 21 days
|
The incidence of symptomatic SARS-CoV-2 infection in different subgroups
Time Frame: Up to 7 days
|
Up to 7 days
|
The incidence and titer of antidrug antibody (ADA)
Time Frame: Up to 21 days
|
Up to 21 days
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
March 31, 2023
Primary Completion (Estimated)
December 31, 2023
Study Completion (Estimated)
June 1, 2024
Study Registration Dates
First Submitted
March 27, 2023
First Submitted That Met QC Criteria
March 27, 2023
First Posted (Actual)
March 28, 2023
Study Record Updates
Last Update Posted (Actual)
September 28, 2023
Last Update Submitted That Met QC Criteria
September 27, 2023
Last Verified
September 1, 2023
More Information
Terms related to this study
Other Study ID Numbers
- HH120-NS311
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on COVID-19
-
University of Roma La SapienzaQueen Mary University of London; Università degli studi di Roma Foro Italico; Bios Prevention SrlCompletedPost Acute Sequelae of COVID-19 | Post COVID-19 Condition | Long-COVID | Chronic COVID-19 SyndromeItaly
-
Yang I. PachankisActive, not recruitingCOVID-19 Respiratory Infection | COVID-19 Stress Syndrome | COVID-19 Vaccine Adverse Reaction | COVID-19-Associated Thromboembolism | COVID-19 Post-Intensive Care Syndrome | COVID-19-Associated StrokeChina
-
Massachusetts General HospitalRecruitingPost Acute COVID-19 Syndrome | Long COVID | Post Acute Sequelae of COVID-19 | Long COVID-19United States
-
Indonesia UniversityRecruitingPost-COVID-19 Syndrome | Long COVID | Post COVID-19 Condition | Post-COVID Syndrome | Long COVID-19Indonesia
-
Erasmus Medical CenterDa Vinci Clinic; HGC RijswijkNot yet recruitingPost-COVID-19 Syndrome | Long COVID | Long Covid19 | Post COVID-19 Condition | Post-COVID Syndrome | Post COVID-19 Condition, Unspecified | Post-COVID ConditionNetherlands
-
Dr. Soetomo General HospitalIndonesia-MoH; Universitas Airlangga; Biotis Pharmaceuticals, IndonesiaRecruitingCOVID-19 Pandemic | COVID-19 Vaccines | COVID-19 Virus DiseaseIndonesia
-
University of Witten/HerdeckeInstitut für Rehabilitationsforschung NorderneyCompletedPost-COVID-19 Syndrome | Long-COVID-19 SyndromeGermany
-
Jonathann Kuo, MDActive, not recruitingSARS-CoV2 Infection | Post-COVID-19 Syndrome | Dysautonomia | Post Acute COVID-19 Syndrome | Long COVID | Long Covid19 | COVID-19 Recurrent | Post-Acute COVID-19 | Post-Acute COVID-19 Infection | Post Acute Sequelae of COVID-19 | Dysautonomia Like Disorder | Dysautonomia Orthostatic Hypotension Syndrome | Post... and other conditionsUnited States
-
University Hospital, Ioannina1st Division of Internal Medicine, University Hospital of IoanninaRecruitingCOVID-19 Pneumonia | COVID-19 Respiratory Infection | COVID-19 Pandemic | COVID-19 Acute Respiratory Distress Syndrome | COVID-19-Associated Pneumonia | COVID 19 Associated Coagulopathy | COVID-19 (Coronavirus Disease 2019) | COVID-19-Associated ThromboembolismGreece
Clinical Trials on HH-120 Nasal Spray
-
Huahui HealthCompleted
-
Beijing Ditan HospitalCompletedCoronavirus Disease 2019(COVID-19)China
-
Beijing Ditan HospitalCompletedCOVID-19 | SARS-CoV-2 InfectionChina
-
Beijing Ditan HospitalCompleted
-
Huahui HealthRecruiting
-
Huahui HealthCompletedCOVID-19 Respiratory InfectionAustralia
-
Huahui HealthCompleted
-
VistaGen Therapeutics, Inc.TerminatedSocial Anxiety DisorderUnited States
-
VistaGen Therapeutics, Inc.RecruitingSocial Anxiety DisorderUnited States
-
VistaGen Therapeutics, Inc.CompletedSocial Anxiety DisorderUnited States